Rothschild Capital Partners LLC Purchases New Shares in Boston Scientific Co. (NYSE:BSX)

Rothschild Capital Partners LLC purchased a new stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 4,126 shares of the medical equipment provider's stock, valued at approximately $369,000.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Boston Scientific by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 132,890,784 shares of the medical equipment provider's stock valued at $11,869,805,000 after acquiring an additional 1,600,062 shares during the period. Wellington Management Group LLP increased its stake in shares of Boston Scientific by 10.2% during the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock valued at $3,230,293,000 after acquiring an additional 3,344,571 shares during the period. Geode Capital Management LLC increased its stake in shares of Boston Scientific by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 30,626,170 shares of the medical equipment provider's stock valued at $2,729,371,000 after acquiring an additional 1,041,329 shares during the period. Capital World Investors increased its stake in shares of Boston Scientific by 28.7% during the fourth quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider's stock valued at $2,492,041,000 after acquiring an additional 6,216,199 shares during the period. Finally, Norges Bank acquired a new position in Boston Scientific in the fourth quarter worth approximately $1,762,522,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

NYSE:BSX traded down $0.50 during mid-day trading on Wednesday, hitting $102.24. 1,713,993 shares of the company's stock traded hands, compared to its average volume of 7,859,563. The firm has a 50 day moving average of $98.56 and a two-hundred day moving average of $95.08. Boston Scientific Co. has a 12 month low of $70.97 and a 12 month high of $107.17. The firm has a market capitalization of $151.22 billion, a price-to-earnings ratio of 81.79, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The firm had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same quarter in the prior year, the company earned $0.56 EPS. The firm's revenue for the quarter was up 20.9% compared to the same quarter last year. On average, equities analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the topic of several recent research reports. Evercore ISI lifted their price target on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Raymond James raised their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research note on Thursday, February 6th. Piper Sandler raised their price objective on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. Needham & Company LLC raised their price objective on shares of Boston Scientific from $113.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Finally, BTIG Research reaffirmed a "buy" rating and issued a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, April 23rd. Twenty-three investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $114.52.

Insiders Place Their Bets

In other Boston Scientific news, EVP John Bradley Sorenson sold 1,201 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the sale, the executive vice president now owns 25,443 shares in the company, valued at approximately $2,704,845.33. This trade represents a 4.51 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Vance R. Brown sold 4,826 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the sale, the senior vice president now owns 36,193 shares of the company's stock, valued at $3,441,592.37. This represents a 11.77 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 138,009 shares of company stock worth $14,407,381. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.